| abstract |
The present invention is to provide a therapeutic agent for interstitial pneumonia that accurately exhibits the effect of superoxide dismutase (SOD), and is represented by the following general formula (I): SOD ′ (Q−B) m (I) (In the formula, SOD ′ represents a residue of superoxide dismutase, Q represents a chemical bridge, B represents a residue of lysolecithin having a hydroxyl group at the 2-position of glycerol excluding a hydrogen atom of the hydroxyl group, m Is the average binding number of lysolecithin to one molecule of superoxide dismutase, and represents an integer of 1 or more) The therapeutic agent for interstitial pneumonia is characterized in that it contains 10 to 100 mg of lecithinized superoxide dismutase represented by the formula, and is in the form of intravenous administration stabilized by addition of sucrose. |